Cipla Limited — Magnesium Exporter Profile
Indian Pharmaceutical Exporter · #2 for Magnesium · $22.0M export value · DGFT Verified
Cipla Limited is the #2 Indian exporter of Magnesium with $22.0M in export value and 440 verified shipments. Cipla Limited holds a 6.1% market share in Magnesium exports across 7 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Magnesium Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Magnesium?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $9.7M | 198 | 72.6% |
| SRI LANKA | $1.4M | 43 | 10.3% |
| CHINA | $995.6K | 107 | 7.4% |
| MALAYSIA | $840.8K | 69 | 6.3% |
| SOUTH AFRICA | $391.9K | 16 | 2.9% |
| TURKEY | $72.6K | 5 | 0.5% |
| SPAIN | $5.4K | 2 | 0.0% |
Cipla Limited exports Magnesium to 7 countries. The largest destination is UNITED STATES accounting for 72.6% of Cipla Limited's Magnesium shipments, followed by SRI LANKA (10.3%) and CHINA (7.4%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Magnesium from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $7.6M | 154 |
| CIPLA USA INC UPS SUPPLY CHAIN SOL | UNITED STATES | $1.9M | 38 |
| BREATHEFREE LANKA PVT LTD | SRI LANKA | $1.2M | 32 |
| CIPLA MALAYSIA SDN BHD | MALAYSIA | $840.8K | 69 |
| SHENZHEN BEIMEI PHARMACEUTICAL CO | CHINA | $541.5K | 52 |
| MEDPRO PHARMACEUTICA PTY LIMITED | SOUTH AFRICA | $250.6K | 9 |
| TEVA PHARMACEUTICALS USA INC | UNITED STATES | $150.0K | 3 |
| TEVA PHARMACEUTICALS USA, INC | UNITED STATES | $135.7K | 3 |
| SHENZHEN BEIMEI PHARMACEUTICAL | CHINA | $129.1K | 13 |
| BREATHEFREE LANKA PRIVATE LIMITED | SRI LANKA | $121.7K | 9 |
Cipla Limited supplies Magnesium to 21 buyers globally. The largest buyer is CIPLA USA INC UPS SUPPLY CHAIN SOLU (UNITED STATES), followed by CIPLA USA INC UPS SUPPLY CHAIN SOL (UNITED STATES) and BREATHEFREE LANKA PVT LTD (SRI LANKA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Magnesium Export Value and How Much Does Cipla Limited Contribute?
India exported $149.3M worth of Magnesium through 8,413 shipments from 669 suppliers to 149 countries, serving 1,612 buyers globally. Cipla Limited contributes $22.0M to this total, accounting for 6.1% of India's Magnesium exports. Cipla Limited ships Magnesium to 7 countries through 21 buyers.
What Is the Average Shipment Value for Cipla Limited's Magnesium Exports?
Cipla Limited's average Magnesium shipment value is $50.0K per consignment, based on 440 shipments totaling $22.0M. The largest destination is UNITED STATES (72.6% of Cipla Limited's Magnesium exports).
How Does Cipla Limited Compare to Other Indian Magnesium Exporters?
Cipla Limited ranks #2 among 669 Indian Magnesium exporters with a 6.1% market share. The top 3 exporters are SUN PHARMACEUTICAL INDUSTRIES LIMITED ($73.0M), CIPLA LIMITED ($22.0M), DR.REDDY'S LABORATORIES LTD ($10.3M). Cipla Limited processed 440 shipments to 7 destination countries.
What Magnesium Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ESOMEPRAZOLE MAGNESIUM FOR DELAYED RELEA | $1.8M | 36 |
| ESOMEPRAZOLE MAGNESIUM FOR DELAYEDRELEASE ORAL SUSPENSION 20MG ; NDC NO.: 69097-528-34; ANDA NO.: 211751 INV | $500.0K | 10 |
| ESOMEPRAZOLE MAGNESIUM FOR DELAYED RELEASE ORAL SUSPENSION 10MG NDC NO. 69097-527-34 ANDA NO. 211752 30 X 3.2 GM | $300.0K | 6 |
| ESOMEPRAZOLE MAGNESIUM FOR DELAYEDRELEASE ORAL SUSPENSION 10MG ; NDC NO.: 69097-527-34; ANDA NO.: 211752 INV | $300.0K | 6 |
| ESOMEPRAZOLE MAGNESIUM DELAYED RELEASE C | $185.7K | 4 |
| ESOMEPRAZOLE MAGNESIUM FOR DELAYED RELEASE ORAL SUSPENSION 20MG ; NDC NO.: 69097528-34; ANDA NO.: 211751 PACK SIZE 30 X | $150.0K | 3 |
| ESOMEPRAZOLE MAGNESIUM FOR DELAYED RELEASE ORAL SUSPENSION 10MG;NDC NO.:69097-527-34;[P/S:30X3.2 GMX3216 PAC=96480 NOS]NOS | $150.0K | 3 |
| ESOMEPRAZOLE MAGNESIUM FOR DELAYED RELEASE ORAL SUSPENSION 10MG;NDC NO.:69097-527-34;[P/S:30X3.2 GMX3228 PAC=96840 NOS]NOS | $150.0K | 3 |
| ESOMEPRAZOLE MAGNESIUM FOR DELAYED RELEASE ORAL SUSPENSION 10MG;NDC NO.:69097-527-34;[P/S:30X3.2 GMX3252 PAC=97560 NOS]NOS | $150.0K | 3 |
| ESOMEPRAZOLE MAGNESIUM FOR DELAYED RELEASE ORAL SUSPENSION 40MG NDC NO. 69097-529-34ANDA NO.211751(INV.QTY.3240 PANOS | $150.0K | 3 |
Cipla Limited exports 249 distinct Magnesium formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ESOMEPRAZOLE MAGNESIUM FOR DELAYED RELEA with 36 shipments worth $1.8M.
Regulatory Requirements: Exporting Magnesium to Key Markets
What Cipla Limited must comply with to export Magnesium to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Magnesium Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $73.0M | 1,459 | 15 | $50.0K |
| 2 | CIPLA LIMITED ★ | $22.0M | 440 | 7 | $50.0K |
| 3 | DR.REDDY'S LABORATORIES LTD | $10.3M | 228 | 4 | $45.1K |
| 4 | BIOCON PHARMA LIMITED | $9.4M | 188 | 1 | $49.9K |
Cipla Limited ranks #2 among 669 Indian Magnesium exporters. Average shipment value of $50.0K compared to the market average of $223.2K. The closest competitors by value are SUN PHARMACEUTICAL INDUSTRIES LIMITED and DR.REDDY'S LABORATORIES LTD.
Which Indian Ports Ship Magnesium Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 657 | 7.8% |
| SAHAR AIR | 582 | 6.9% |
| JNPT/ NHAVA SHEVA SEA | 481 | 5.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 468 | 5.6% |
| JNPT | 387 | 4.6% |
| CMA CGM LOGISTICS PARK ICD | 303 | 3.6% |
| CMA CGM LOGISTICS PARK ICD (INCPL6) | 274 | 3.3% |
| DELHI AIR | 258 | 3.1% |
What Other Vitamins & Supplements Products Does Cipla Limited Export?
Cipla Limited also exports these vitamins & supplements products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Cipla Limited's Magnesium Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Magnesium, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Magnesium — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Magnesium shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 440 individual customs records matching Cipla Limited exporting Magnesium, covering 249 formulations to 7 countries via 21 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 149+ countries, 1,612+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Magnesium Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Magnesium exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Magnesium Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Magnesium. For current shipment-level data, contact TransData Nexus.